By Mill Chart
Last update: Nov 10, 2023
Our stock screening tool has pinpointed CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as a growth stock that isn't overvalued. NASDAQ:CORT is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:CORT has received a 7 out of 10:
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:CORT has received a 5 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:CORT, the assigned 8 is a significant indicator of profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Check the latest full fundamental report of CORT for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (4/25/2024, 7:00:00 PM)
After market: 22.21 0 (0%)22.21
-0.27 (-1.2%)
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...